Adjuvant chemotherapy for non-small cell lung cancer

Cancer Investigation

Volumn 25, Issue 4, 2007, Pages 217-225

  Solomon, Benjamin ^a   Bunn Jr , Paul A ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Cisplatin based adjuvant chemotherapy; Non small cell lung cancer; Postoperative radiotherapy

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; NITROSOUREA; PACLITAXEL; PLATINUM; UFT; VINBLASTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DRUG FATALITY; FEBRILE NEUTROPENIA; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; META-ANALYSIS;

EID: 34347383145     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701206281     Document Type: Article

References (52)

1. Jemal, A.; Siegel, R.; Ward, E.; et al. Cancer Statistics, 2006. CA Cancer J. Clin. 2006, 56 (2), 106-130.
2. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global Cancer Statistics, 2002. CA Cancer J. Clin. 2005, 55 (2), 74.
3. Mountain, C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111 (6), 1710-1717.
4. Van Rens, M.T.M.; De la Riviere, A.B.; Elbers, H.R.J.; Van den Bosch, J.M.M. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000, 117 (2), 374.
5. Naruke, T.; Tsuchiya, R.; Kondo, H.; Asamura, H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Annals of Thoracic Surgery 2001, 71 (6), 1759.
6. Fang, D.; Zhang, D.; Huang, G.; Zhang, R.; Wang, L.; Zhang, D. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1,905 cases. Annals of Thoracic Surgery 2001, 72 (4), 1155.
7. Goya, T.; Asamura, H.; Yoshimura, H.; et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005, 50 (2), 227.
8. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311 (7010), 899-909.
9. Keller, S.M.; Adak, S.; Wagner, H.; et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N. Engl. J. Med. 2000, 343 (17), 1217-1222.
10. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998, 352 (9124), 257-263.
11. Burdett, S.; Stewart, L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005, 47 (1), 81.
12. Scagliotti, G.V.; Fossati, R; Torri, V.; et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J. Natl. Cancer Inst. 2003, 95 (19), 1453-1461.
13. Arriagada, R.; Bergman, B.; Dunant, A.; Le Chevalier, T.; Pignon, J.P.; Vansteenkiste, J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 2004, 350 (4), 351-360.
14. Waller, D.; Peake, M.D.; Stephens, R.J.; et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur. J. Cardiothorac. Surg. 2004, 26 (1), 173-182.
15. Winton, T.; Livingston, R.; Johnson, D.; et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med.; 2005, 352 (25), 2589-2597.
16. Strauss, G.; Herndon, J.; Maddaus, M.A.; et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004, 22 (Suppl. 14), 7019.
17. Strauss, G.M.; Herndon, J.E.; Maddaus, M. A.; et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 2006, 24 (Suppl. 18S), No. 18S, 7007.
18. Douillard, J.; Rosell, R.; Delena, M.; Legroumellec, A.; Torres, A.; Carpagnano, F. ANITA: Phase III adjuvant vinorelbine (N) and cis-platin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up.On behalf of the Adjuvant Navelbine International Trialist Association. Part I of II. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings. 2005, 23 (Suppl. 16), 7013.
19. Kato, H.; Ichinose, Y.; Ohta, M.; et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 2004, 350 (17), 1713-1721.
20. Nakagawa, M.; Tanaka, F.; Tsubota, N.; et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG) - the 4th study. Ann. Oncol. 2005, 16 (1), 75-80.
21. Wada, H.; Hitomi, S.; Teramatsu, T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J. Clin. Oncol. 1996, 14 (4), 1048-1054.
22. Endo, C.; Saito, Y.; Iwanami, H.; et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-East Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003, 40 (2), 181.
23. Tada, H.; Yasumitsu, T.; Iuchi, K.; Taki, T.; Komada, K.; Matsumura, A. Randomized control study of adjuvant chemotherapy with UFT alone or plus cisplatin and vindesine in patients with completely resected non-small cell lung cancer. Lung Cancer 2003, 41 (2) S54, 0-182.
24. Imaizumi, M. A randomized trial of postoperative adjuvant chemotherapy for p-stage I non-small cell lung cancer (4th cooperative study). Lung Cancer 2003, 41 (2) S54, 0-182.
25. Hamada, C.; Tanaka, F.; Ohta, M.; et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J. Clin. Oncol. 2005, 23 (22), 4999-5006.
26. Hotta, K.; Matsuo, K.; Ueoka, H.; Kiura, K.; Tabata, M.; Tanimoto, M Role of adjuvant chemotherapy in patients with resected nonsmall-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J. Clin. Oncol. 2004, 22 (19), 3860-3867.
27. Sedrakyan, A.; Van Der Meulen, J.; O'Byrne, K.; Prendiville, J.; Hill, J.; Treasure, T. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J. Thorac. Cardiovasc. Surg. 2004, 128 (3), 414-419.
28. Berghmans, T.; Paesmans, M.; Meert, A.P.; et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005, 49 (1), 13-23.
29. Pignon, J.P.; Tribodet, H.; Scagliotti, G.V.; et al. A pooled analysis of five randomized clinical trials including 4,584 patients. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 2006, 24 (Suppl. 18S), 7008.
30. Melo, M.J.; Barradas, P.; Costa, A.; Cristovao, M.; Alves, P. Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic nonsmall cell lung cancer (NSCLC): mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option. Proc. Am. Soc. Clin. Oncol. 2002, 21 (Abstr. 1205).
31. Rudd, R.M.; Gower, N.H.; Spiro, S.G.; et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J. Clin. Oncol. 2005, 23 (1), 142-153.
32. Alberola, V.; Camps, C.; Provencio, M.; et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J. Clin. Oncol. 2003, 21 (17), 3207-3213.
33. Souquet, P.J.; Tan, E.H.; Rodrigues Pereira, J.; et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann. Oncol. 2002, 13 (12), 1853-1861.
34. Scagliotti, G.V.; De Marinis, F.; Rinaldi, M.; et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 2002, 20 (21), 4285-4291.
35. Kelly, K.; Crowley, J.; Bunn, P.A. Jr.; et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 2001, 19 (13), 3210-3218.
36. Sandler, A.B.; Gray, R.; Brahmer, J.; et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Part I of II. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings. 2005, 23 (Suppl. 16S), 4.
37. Soria, J.; Haddad, V.; Olaussen, K.A.; et al. Immunohistochemical staining of the Excision Repair Cross-Complementing 1 (ERCC1) protein as predictor for benefit of adjuvant chemotherapy (CT) in the International Lung Cancer Trial (IALT). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006, 24 (Suppl.18S), 7010.
38. Bepler, G.; Sharma, S.; Cantor, A.; et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 2004, 22 (10), 1878-1885.
39. Mountain, C.F.; McMurtrey, M.J.; Frazier, O.H.; Barkley, T.H.; Valdivieso, M. Present status of postoperative adjuvant therapy for lung cancer. The Cancer Bulletin 1980, 32 (3), 108-112.
40. Feld, R.; Rubinstein, L.V.; Weisenberger, T.H. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J. Clin. Oncol. 1984, 2 (12), 1352-1358.
41. Pairolero, P.C.; Williams, D.E.; Bergstralh, E.J.; Piehler, J.M.; Bernatz, P.E.; Payne, W.S. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann. Thorac. Surg. 1984, 38 (4), 331-338.
42. Harpole, D.H. Jr.; Herndon, J.E. 2nd; Young, W.G. Jr.; Wolfe, W.G.; Sabiston, D.C. Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995, 76 (5), 787-796.
43. Yano, T,.; Yokoyama, H.; Inoue, T.; et al. The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. Comparison between pN0 disease and pN2 disease. J. Thorac. Cardiovasc. Surg. 1994, 108 (4), 680-683.
44. Martini, N.; Bains, M.S.; Burt, M.E.; et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg. 1995, 109 (1), 120-129.
45. Cangemi, V.; Volpino, P.; D'Andrea, N.; et al. Local and/or distant recurrences in T1-2/N0-1 non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 1995, 9 (9), 473-478.
46. Al-Kattan, K.; Sepsas, E.; Fountain, S.W.; Townsend, E.R. Disease recurrence after resection for stage I lung cancer. Eur. J. Cardiothorac. Surg. 1997, 12 (3), 380.
47. Mineo, T.C.; Ambrogi, V.; Corsaro, V.; Roselli, M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 2001, 20 (2), 378-384.
48. Xu, G.; Rong, T.; Lin, P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin. Med. J. (Engl.) 2000, 113 (7), 617-620.
49. Tada, H.; Tsuchiya, R.; Ichinose, Y.; et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004, 43 (2), 167-173.
50. SGACLC A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur. J. Surg. Oncol. 1995, 21 (1), 69-77.
51. Wada, H.; Hitomi, S.; Teramatsu, T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer : West Japan Study Group for Lung Cancer Surgery. J. Clin. Oncol. 1996, 14 (4), 1048-1054.
52. Wada, H.; Miyahara, R.; Tanaka, F.; Hitomi, S. Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegaful) in resected stage I-II NSCLC (nonsmall cell lung cancer): a randomized clinical trial. West Japan Study Group for Lung Cancer Surgery (WJSG). Eur. J. Cardiothorac. Surg. 1999, 15 (4), 438-443.